^
Association details:
| Biomarker: | TCF3-PBX1 fusion |
|---|---|
| Cancer: | B Acute Lymphoblastic Leukemia |
| Drug Class: | CD19-targeted CAR-T immunotherapy |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Anti-CD19 chimeric antigen receptors T cells for the treatment of relapsed or refractory E2A-PBX1 positive acute lymphoblastic leukemia: report of three cases
Published date:
04/02/2019
Excerpt:
Patients with relapsed or refractory E2A-PBX1 positive acute B lymphoblastic leukemia (B-ALL) receiving anti-CD19 chimeric antigen receptor T cells (CAR-T) were retrospectively assessed to evaluate the efficacy...Our findings suggest that anti-CD19 CAR-T cells therapy with a remarkable MRD eradicating ability might be an effective option for patients with relapsed and refractory E2A-PBX1 positive B-ALL.
DOI:
https://doi.org/10.1080/10428194.2018.1533127
